Ships within 7-10 business days.
| Method | ELISA |
|---|---|
| Sample Type (Matrix) | Serum, EDTA Plasma |
| Sample Volume | 25 µL |
| Species | Human |
| Incubation Time | 3h |
| Size | 96 wells |
| Regulatory Status | Health Canada Licensed. |
The IDKmonitor® Infliximab Total ADA ELISA (Health Canada) is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.
Health Canada Licensed.
For Laboratory Professional Use Only.
Not for sale in the U.S. Please contact us to order or get a quote.
If you’re in the U.S., we offer an RUO version of this kit: KR9654
Manufactured by Immundiagnostik AG.
Also available:
This test is for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).
During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced, and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.
Adding an acidic solution stops the enzymatic reaction. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.
Fill out the form to let us know how we can help you, and someone will be in touch with you soon.
